PURPOSE This guideline reviews the evidence and provides recommendations for the indications and appropriate techniques of radiation therapy (RT) in the treatment of nonmetastatic cervical cancer. METHODS The American Society for Radiation Oncology convened a task force to address 5 key questions focused on the use of RT in definitive and postoperative management of cervical cancer. These questions included the indications for postoperative and definitive RT, the use of chemotherapy in sequence or concurrent with RT, the use of intensity modulated radiation therapy (IMRT), and the indications and techniques of brachytherapy. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for grading evidence quality and recommendation strength. RESULTS The guideline recommends postoperative RT for those with intermediate risk factors, and chemoradiation for those with high-risk factors. In the definitive setting, chemoradiation is recommended for stages IB3-IVA, and RT or chemoradiation is conditionally recommended for stages IA1-IB2 if medically inoperable. IMRT is recommended for postoperative RT and conditionally recommended for definitive RT, for the purposes of reducing acute and late toxicity. Brachytherapy is strongly recommended for all women receiving definitive RT, and several recommendations are made for target dose and fractionation, the use of intraoperative imaging, volume-based planning, and recommendations for doses limits for organs at risk. CONCLUSIONS There is strong evidence supporting the use of RT with or without chemotherapy in both definitive and postoperative settings. Brachytherapy is an essential part of definitive management and volumetric planning is recommended. IMRT may be used for the reduction of acute and late toxicity. The use of radiation remains an essential component for women with cervical cancer to achieve cure.
Abstract Neutrino–nuclear responses associated with astro-neutrinos, single beta decays and double beta decays are crucial in studies of neutrino properties of interest for astro-particle physics. The present report reviews briefly recent studies of the neutrino–nuclear responses from both experimental and theoretical points of view in order to obtain a consistent understanding of the many facets of the neutrino–nuclear responses. Subjects discussed in this review include (i) experimental studies of neutrino–nuclear responses by means of single beta decays, charge-exchange nuclear reactions, muon- photon- and neutrino–nuclear reactions, and nucleon-transfer reactions, (ii) implications of and discussions on neutrino–nuclear responses for single beta decays, for astro-neutrinos, and for astro-neutrino nucleosynthesis, (iii) theoretical aspects of neutrino–nuclear responses for beta and double beta decays, for nuclear muon capture and for neutrino–nucleus scattering, and (iv) critical discussions on nucleonic and non-nucleonic spin–isospin correlations and renormalization (quenching or enhancement) effects on the axial weak coupling. Remarks are given on perspectives of experimental and theoretical studies of the neutrino–nuclear responses and on future experiments of double beta decays.
PURPOSE Several sentinel phase III randomized trials have recently been published challenging traditional radiation therapy (RT) practices for small cell lung cancer (SCLC). This American Society for Radiation Oncology guideline reviews the evidence for thoracic RT and prophylactic cranial irradiation (PCI) for both limited-stage (LS) and extensive-stage (ES) SCLC. METHODS The American Society for Radiation Oncology convened a task force to address 4 key questions focused on indications, dose fractionation, techniques and timing of thoracic RT for LS-SCLC, the role of stereotactic body radiation therapy (SBRT) compared with conventional RT in stage I or II node negative SCLC, PCI for LS-SCLC and ES-SCLC, and thoracic consolidation for ES-SCLC. Recommendations were based on a systematic literature review and created using a consensus-building methodology and system for grading evidence quality and recommendation strength. RESULTS The task force strongly recommends definitive thoracic RT administered once or twice daily early in the course of treatment for LS-SCLC. Adjuvant RT is conditionally recommended in surgically resected patients with positive margins or nodal metastases. Involved field RT delivered using conformal advanced treatment modalities to postchemotherapy volumes is also strongly recommended. For patients with stage I or II node negative disease, SBRT or conventional fractionation is strongly recommended, and chemotherapy should be delivered before or after SBRT. In LS-SCLC, PCI is strongly recommended for stage II or III patients who responded to chemoradiation, conditionally not recommended for stage I patients, and should be a shared decision for patients at higher risk of neurocognitive toxicities. In ES-SCLC, radiation oncologist consultation for consideration of PCI versus magnetic resonance surveillance is strongly recommended. Lastly, the use of thoracic RT is strongly recommended in select patients with ES-SCLC after chemotherapy treatment, including a conditional recommendation in those responding to chemotherapy and immunotherapy. CONCLUSIONS RT plays a vital role in both LS-SCLC and ES-SCLC. These guidelines inform best clinical practices for local therapy in SCLC.
PURPOSE The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy (RT) for small-cell lung cancer (SCLC). Because of the relevance of this topic to ASCO membership, ASCO reviewed the guideline, applying a set of procedures and policies used to critically examine guidelines developed by other organizations. METHODS The ASTRO guideline on RT for SCLC was reviewed for developmental rigor by methodologists. Then, an ASCO Expert Panel reviewed the content and the recommendations. RESULTS The ASCO Expert Panel determined that the recommendations from ASTRO guideline on RT for SCLC, published in June 2020, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed ASTRO guideline on RT for SCLC with a few discussion points. RECOMMENDATIONS Recommendations addressed thoracic radiotherapy for limited-stage SCLC, role of stereotactic body radiotherapy in stage I or II node-negative SCLC, prophylactic cranial radiotherapy, and thoracic consolidation for extensive-stage SCLC.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
In 2017, the ASTRO Board of Directors prioritized radiopharmaceutical therapy (RPT) as a leading area for new therapeutic development, and the ASTRO RPT Workgroup was created. Herein the Workgroup has developed a framework for RPT curriculum development upon which education leaders can build to integrate this modality into radiation oncology resident education. Through this effort, the Workgroup aims to provide a guide to ensure robust training in an emerging therapeutic area within the context of existing radiation oncology training in radiation biology, medical physics, and clinical radiation oncology. The framework first determines the core RPT knowledge required to select patients, prescribe, safely administer, and manage related adverse events. Then, it defines the most important topics for preparing residents for clinical RPT planning and delivery. This framework is designed as a tool to supplement the current training that exists for radiation oncology residents. The final document was approved by the ASTRO Board of Directors in the Fall of 2021.
PURPOSE The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic disease after exhaustion of local treatment options as well as those with metastatic hormone-sensitive prostate cancer. Please refer to Part II for discussion of the management of castration-resistant disease. MATERIALS AND METHODS The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. A research librarian conducted searches in Ovid MEDLINE (1998 to January Week 5 2019), Cochrane Central Register of Controlled Trials (through December 2018), and Cochrane Database of Systematic Reviews (2005 through February 6, 2019). An updated search was conducted prior to publication through January 20, 2020. The methodology team supplemented searches of electronic databases with the studies included in the prior AUA review and by reviewing reference lists of relevant articles. RESULTS The Advanced Prostate Cancer Panel created evidence- and consensus-based guideline statements to aid clinicians in the management of patients with advanced prostate cancer. Such statements are summarized in figure 1 and detailed herein. CONCLUSIONS This guideline attempts to improve a clinician's ability to treat patients diagnosed with advanced prostate cancer. Continued research and publication of high-quality evidence from future trials will be essential to improve the level of care for these patients.
Madhusudan Ghosh, Payel Santra, SK Asif Iqbal
et al.
Scientific research requires reading and extracting relevant information from existing scientific literature in an effective way. To gain insights over a collection of such scientific documents, extraction of entities and recognizing their types is considered to be one of the important tasks. Numerous studies have been conducted in this area of research. In our study, we introduce a framework for entity recognition and identification of NASA astrophysics dataset, which was published as a part of the DEAL SharedTask. We use a pre-trained multilingual model, based on a natural language processing framework for the given sequence labeling tasks. Experiments show that our model, Astro-mT5, out-performs the existing baseline in astrophysics related information extraction.
Large Language Models (LLMs) are transforming software engineering tasks, including code vulnerability detection-a critical area of software security. However, existing methods often rely on resource-intensive models or graph-based techniques, limiting their accessibility and practicality. This paper introduces K-ASTRO, a lightweight Transformer model that combines semantic embeddings from LLMs with structural features of Abstract Syntax Trees (ASTs) to improve both efficiency and accuracy in code vulnerability detection. Our approach introduces an AST-based augmentation technique inspired by mutation testing, a structure-aware attention mechanism that incorporates augmented AST features, and a joint adaptation pipeline to unify code semantics and syntax. Experimental results on three large-scale datasets, including BigVul, DiverseVul, and PrimeVul-demonstrate state-of-the-art performance while enabling rapid inference on CPUs with minimal training time. By offering a scalable, interpretable, and efficient solution, K-ASTRO bridges the gap between LLM advancements and practical software vulnerability detection, providing open-sourced tools to foster further research.
The study of flaring astrophysical events in the multi-messenger approach requires instantaneous follow-up observations to better understand the nature of these events through complementary observational data. We present Astro-COLIBRI as a platform that integrates specific tools in the real-time multi-messenger ecosystem. The Astro-COLIBRI platform bundles and evaluates alerts about transients from various channels. It further automates the coordination of follow-up observations by providing and linking detailed information through its comprehensible graphical user interface. We present the functionalities with documented examples of Astro-COLIBRI usage through the community since its public release in August 2021. We highlight the use cases of Astro-COLIBRI for planning follow-up observations by professional and amateur astronomers, as well as checking predictions from theoretical models.
V. E. Sarris, Constantinos Costa, Panos K. Chrysanthis
CAPRIO is an indoor-outdoor pedestrian path rec-ommendation system that optimizes for shortest distance. Its path-finding algorithm, ASTRO, takes into account a set of user-provided congestion constraints and as such can recommend paths that can reduce the risk of COVID-19 exposure. In this paper, we extend ASTRO to consider the changes on congestion when providing path recommendations for overlapping requests. Our new algorithm, called ASTRO-K, can provide K alternative paths that satisfy the congestion constraints of all the path requests within a short time-window. Our experimental eval-uation is conducted using two real-world datasets and shows that ASTRO-K can reduce the total average congestion of the recommended paths up to 4.5X with the trade-off of up to 7% increased total path time.
Background: Coronary artery calcium (CAC) is a powerful novel risk indicator for atherosclerotic cardiovascular disease (ASCVD). Currently, there is no available ASCVD risk prediction tool that integrates traditional risk factors and CAC. Methods: To develop a CAC ASCVD risk tool for younger individuals in the general population, subjects aged 40 to 65 without prior cardiovascular disease from 3 population-based cohorts were included. Cox proportional hazards models were developed incorporating age, sex, systolic blood pressure, total and high-density lipoprotein cholesterol, smoking, diabetes mellitus, hypertension treatment, family history of myocardial infarction, high-sensitivity C-reactive protein, and CAC scores (Astro-CHARM model [Astronaut Cardiovascular Health and Risk Modification]) as dependent variables and ASCVD (nonfatal/fatal myocardial infarction or stroke) as the outcome. Model performance was assessed internally, and validated externally in a fourth cohort. Results: The derivation study comprised 7382 individuals with a mean age 51 years, 45% women, and 55% nonwhite. The median CAC was 0 (25th, 75th [0,9]), and 304 ASCVD events occurred in a median 10.9 years of follow-up. The c-statistic was 0.784 for the risk factor model, and 0.817 for Astro-CHARM (P<0.0001). In comparison with the risk factor model, the Astro-CHARM model resulted in integrated discrimination improvement (0.0252), and net reclassification improvement (0.121; P<0.0001), as well. The Astro-CHARM model demonstrated good discrimination (c=0.78) and calibration (Nam-D’Agostino &khgr;2, 13.2; P=0.16) in the validation cohort (n=2057; 55 events). A mobile application and web-based tool were developed to facilitate clinical application of this tool (www.AstroCHARM.org). Conclusion: The Astro-CHARM tool is the first integrated ASCVD risk calculator to incorporate risk factors, including high-sensitivity C-reactive protein and family history, and CAC data. It improves risk prediction in comparison with traditional risk factor equations and could be useful in risk-based decision making for cardiovascular disease prevention in the middle-aged general population.
BACKGROUND Re-operation rates following breast-conserving surgery (BCS) for early invasive breast cancer are highly variable, largely due to uncertainty regarding adequate margins. The 2014 SSO-ASTRO guidelines recommended "no ink on tumor" as adequate margins. We evaluated the effect of guideline implementation on re-operation following BCS at our regional cancer center. METHODS Retrospective chart review was performed on records for patients with early invasive breast carcinoma undergoing BCS between February 2011 and May 2017. Time period, pathologic margin status, patient and tumor characteristics were assessed for their impact on re-operation rates. RESULTS Overall re-operation rate decreased following the guidelines release (OR 0.28, 95% C.I. 0.15-0.51, p = <0.0001), with an unadjusted decrease of 3.89%. Re-operations on both close (OR 0.17, 95% C.I. 0.07-0.40, p = <0.0001) and widely negative (OR 0.20, 95% C.I. 0.05-0.77, p = 0.02) margins decreased in the post-guidelines time period. CONCLUSION SSO-ASTRO margins guideline release was associated with decreased re-operation. Furthermore, re-operations rates decreased in patients with pathologically negative margins, the target population the guidelines were meant to address.